Page last updated: 2024-12-08
norethindrone enanthate
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
norethindrone enanthate: structure in Negwer, 5th ed, #5612 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 229295 |
| CHEMBL ID | 3187229 |
| CHEBI ID | 34894 |
| SCHEMBL ID | 354296 |
| MeSH ID | M0082450 |
Synonyms (71)
| Synonym |
|---|
| AC-6835 |
| [(8r,9s,10r,13s,14s,17r)-17-ethynyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] heptanoate |
| 3836-23-5 |
| 19-nor-17.alpha.-pregn-4-en-20-yn-3-one, heptanoate |
| 19-nor-17.alpha.-pregn-4-en-20-yn-3-one, heptanate |
| nsc-22846 |
| noristerat |
| nsc22846 |
| 17.alpha.-ethynyl-19-nortestosterone enanthate |
| 17.alpha.-ethynyl-19-nortestosterone 17-heptanoate |
| 17.alpha.-ethynyl-17.beta.-heptanoyloxy-4-estren-3-one |
| NEE , |
| 19-nor-17.alpha.-pregnen-20-ynone, 17.beta.-heptanoyloxy- |
| sh 393 |
| norlutin enanthate |
| norethindrone enanthate |
| norethisterone enanthate |
| wln: l e5 b666 ov mutj e1 fov6 f1uu1 |
| 17.alpha.-ethinyl-19-nortestosterone enanthate |
| brn 3176529 |
| 17alpha-ethynyl-19-nortestosterone 17-heptanoate |
| 19-nor-17alpha-pregnen-20-ynone, 17beta-heptanoyloxy- |
| 19-nor-17alpha-pregn-4-en-20-yn-3-one, 17-hydroxy-, heptanate |
| 17-alpha-ethinyl-19-nortestosterone enanthate |
| 17-alpha-ethynyl-17-beta-heptanoyloxy-4-estren-3-one |
| 19-norpregn-4-en-20-yn-3-one, 17-((1-oxoheptyl)oxy)-, (17alpha)- |
| 17-beta-heptanoyloxy-17-alpha-ethynyl-4-oestren-3-one |
| 17alpha-ethinyl-19-nortestosterone enanthate |
| norethisterone oenanthate |
| sovel |
| 17alpha-ethynyl-19-nortestosterone enanthate |
| lg 202 |
| norethisterone enantate |
| (17alpha)-17-((1-oxoheptyl)oxy)-19-norpregn-4-en-20-yn-3-one |
| ccris 6526 |
| 19-nor-17-alpha-pregnen-20-ynone, 17-beta-heptanoyloxy- |
| 19-nor-17alpha-pregn-4-en-20-yn-3-one, 17-hydroxy-, heptanoate |
| einecs 223-326-7 |
| norigest |
| 3-oxo-19-nor-17alpha-pregn-4-en-20-in-17-yl-heptanot |
| 17alpha-ethynyl-17beta-heptanoyloxy-4-estren-3-one |
| D08285 |
| noristerat (tn) |
| cas-3836-23-5 |
| dtxcid9028590 |
| tox21_113027 |
| dtxsid2048664 , |
| hy3s2k0j0f , |
| unii-hy3s2k0j0f |
| AKOS015896289 |
| sh-8.0393 |
| norethisterone enantate [who-ip] |
| 19-norpregn-4-en-20-yn-3-one, 17-((1-oxoheptyl)oxy)-, (17.alpha.)- |
| norethisterone enantate [mart.] |
| zk-5410 |
| norethisterone enantate [who-dd] |
| norethisteroni enantas [who-ip latin] |
| S6589 |
| SCHEMBL354296 |
| CHEBI:34894 , |
| CHEMBL3187229 |
| norethisterone enantate (norethindrone enanthate) |
| DB14678 |
| norethindrone heptanoate |
| AS-13385 |
| BCP10922 |
| Q7050956 |
| CS-0019768 |
| norethisterone-enanthate |
| 19-norpregn-4-en-20-yn-3-one, 17-[(1-oxoheptyl)oxy]-, (17a)- |
| HY-A0285 |
Research Excerpts
Toxicity
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " Due to wide intersubject variations there were no statistically significant differences in the pharmacokinetic parameters for the different groups but there were significant correlations between the dose and the mean values for these parameters." | ( Pharmacokinetics of different doses of norethisterone oenanthate. Bye, PG; Elder, M; Fotherby, K; Hamawi, A; Howard, G, 1984) | 0.27 |
| " Due to wide intersubject variations, there were no statistically significant differences in the pharmacokinetic paraetmers for the different groups but there were significant correlations between the dose and the mean values for these parameters." | ( Pharmacokinetics of different doses of norethisterone oenanthate. Bye, PG; Elder, M; Fotherby, K; Hamawi, A; Howard, G, 1984) | 0.27 |
| " Extremely wide variations were observed between women in the various calculated pharmacokinetic parameters." | ( Variability of pharmacokinetic parameters for contraceptive steroids. Fotherby, K, 1983) | 0.27 |
| " The elimination half-life was 5-10 days." | ( Pharmacokinetics of orally administered norethisterone enanthate in rabbit, monkey, and women. Nair, KM; Ravinder, P; Shatrugna, V; Sivakumar, B, 1997) | 0.3 |
| " Washing the skin after 10 min does not influence the pharmacokinetic profile and thus significantly reduces the risk of contamination of female partners or infants." | ( Pharmacokinetics of a new transdermal testosterone gel in gonadotrophin-suppressed normal men. Eickenberg, U; Kemper, S; Lemmnitz, G; Nieschlag, E; Rolf, C, 2002) | 0.31 |
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| " As a prerequisite for a planned multicenter male contraceptive efficacy study, we studied the pharmacokinetics of 2 doses of TU alone or in combination with norethisterone enanthate (NETE) in a prospective 2-center study, randomized for TU dose in each center." | ( Pharmacokinetics of testosterone undecanoate injected alone or in combination with norethisterone enanthate in healthy men. Cerpolini, S; Christensen, PD; Hull, L; Lumbreras, L; Meriggiola, C; Ng, CM; Pelusi, G; Qoubaitary, A; Swerdloff, RS; Wang, C, ) | 0.13 |
Bioavailability
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " This even occurs with those methods which do not usually suppress ovulation, but the disturbance is generally less severe with lower dosage systems." | ( Menstrual changes associated with progestogen-only contraception. Fraser, IS, 1986) | 0.27 |
| " The weight gain of the highest NETE plus TU dosage was mainly because of gain in muscle mass." | ( A placebo-controlled, randomized clinical trial using testosterone undecanoate with injectable norethisterone enanthate: effect on anthropometric, metabolic and biochemical parameters. Cerpolini, S; Costantino, A; Meriggiola, MC; Pasquali, R; Pelusi, C; Pelusi, G, 2011) | 0.37 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| steroid ester | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (7)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| AR protein | Homo sapiens (human) | Potency | 1.0657 | 0.0002 | 21.2231 | 8,912.5098 | AID743035; AID743036; AID743040; AID743053; AID743063 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 24.9929 | 0.0002 | 14.3764 | 60.0339 | AID720691; AID720692; AID720719 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 10.2637 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075; AID743077; AID743078; AID743079; AID743091 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 11.4524 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743066; AID743067 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 32.8610 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID720552 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 3.3491 | 0.0119 | 17.9420 | 71.5630 | AID651632 |
| Ataxin-2 | Homo sapiens (human) | Potency | 3.3491 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (141)
Molecular Functions (40)
Ceullar Components (26)
Bioassays (4)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (178)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 76 (42.70) | 18.7374 |
| 1990's | 31 (17.42) | 18.2507 |
| 2000's | 34 (19.10) | 29.6817 |
| 2010's | 28 (15.73) | 24.3611 |
| 2020's | 9 (5.06) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 20.59
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.59) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 49 (26.06%) | 5.53% |
| Reviews | 23 (12.23%) | 6.00% |
| Case Studies | 1 (0.53%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 115 (61.17%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Clinical Trials (3)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PROMES: PROspective, Non-Interventional, Observational, Longitudinal Study to Describe the Safety Profile of MESIGYNA® (Norethisterone Enantate 50 mg and Estradiol Valerate 5 mg) as a Contraceptive Method for Women in Reproductive Age at the Outpatient Cl [NCT03901131] | 296 participants (Actual) | Observational | 2019-08-26 | Completed | |||
| Hormonal Contraception and Bacterial Vaginosis (HCBV): The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis Among Women at High Risk for HIV Infection in Kampala, Uganda [NCT02905890] | Phase 4 | 250 participants (Actual) | Interventional | 2017-10-02 | Completed | ||
| Effects of One-to-one Service on the Continuation and Satisfaction of Combined Injectable Contraceptive Use. [NCT05362019] | 400 participants (Anticipated) | Interventional | 2022-05-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||